A Study of Mirikizumab (LY3074828) in Healthy Participants

NCT02568423 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Mirikizumab - IV
DRUG: Mirikizumab - SC
DRUG: Placebo - IV
DRUG: Placebo - SC

Sponsor

Eli Lilly and Company